<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Synthorx, Inc.

    Synthorx, Inc.

    Synthorx is a biotechnology company focused on prolonging and improving the lives ...

    Synthorx is a biotechnology company focused on ...

    Filing Type:    PU
    TrovaGene, Inc.

    TrovaGene, Inc.

    Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...

    Trovagene is a clinical-stage, oncology therape...

    Filing Type:    PU
    Corbus Pharmaceuticals Holdings, Inc.

    Corbus Pharmaceuticals Holdings, Inc.

    Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical c...

    Corbus Pharmaceuticals Holdings, Inc. is a Phas...

    Filing Type:    PU
    Audentes Therapeutics, Inc.

    Audentes Therapeutics, Inc.

    Audentes Therapeutics is a leading AAV-based genetic medicines company focused on ...

    Audentes Therapeutics is a leading AAV-based ge...

    Filing Type:    PU
    NeuroMetrix, Inc.

    NeuroMetrix, Inc.

    Founded in 1996 as a spinoff from the Harvard-MIT Division of Health Sciences and ...

    Founded in 1996 as a spinoff from the Harvard-M...

    Filing Type:    PU
    Advaxis, Inc.

    Advaxis, Inc.

    Advaxis was founded on the vision that no one should suffer from the burdens of ca...

    Advaxis was founded on the vision that no one s...

    Filing Type:    PU
    Gritstone Oncology, Inc.

    Gritstone Oncology, Inc.

    Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight mu...

    Gritstone Oncology is developing tumor-specific...

    Filing Type:    PU
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    Compugen Ltd.

    Compugen Ltd.

    Compugen is a drug discovery company with a unique, broadly applicable, predictive...

    Compugen is a drug discovery company with a uni...

    Filing Type:    PU
    ESSA Pharma Inc.

    ESSA Pharma Inc.

    With a focus on the development of small molecule drugs for the treatment of cance...

    With a focus on the development of small molecu...

    Filing Type:    PU
    Agios Pharmaceuticals, Inc.

    Agios Pharmaceuticals, Inc.

    Agios is a biopharmaceutical company passionately committed to applying our scient...

    Agios is a biopharmaceutical company passionate...

    Filing Type:    PU
    Celcuity Inc.

    Celcuity Inc.

    Celcuity is a cellular analysis company that is discovering new cancer sub-types a...

    Celcuity is a cellular analysis company that is...

    Filing Type:    PU
    ©2025 National Investor Network. All Rights Reserved.